On November 12, 2026, Eli Lilly China announced that its oral small-molecule GLP-1 receptor agonist, orforglipron calcium tablets, has received marketing approval from the National Medical Products Administration (NMPA). The medication is indicated for long-term weight management in adults—as an adjunct to a reduced-calorie diet and increased physical activity—who have an initial body mass index (BMI) of ≥30 kg/m2, or an initial BMI of ≥27 kg/m2 but <30 kg/m2 with at least one weight-related comorbidity.
This marks the first oral GLP-1 receptor agonist approved for adult weight management in China, signaling the entry of oral small-molecule drugs into the Chinese obesity treatment landscape.